May 7, 2018 News by Patricia Silva, PhD ‘MS from Inside Out’ Uses Vitural Reality to Show Canadians Life with This Disease For Multiple Sclerosis Awareness Month and leading up to May 30,Ā World MS Day, Ā EMD Serono, Canada, is taking a virtual reality program to three Canadian cities to help educate people about multiple sclerosis and its impact. The biopharmaceutical company wants to help people better understand what it…
May 3, 2018 News by Alice MelĆ£o, MSc Mavenclad Effective in Treating Highly Active MS, New CLARITY Analysis Shows An additional analysis of data from the CLARITY study confirmed the long-term benefits of treatment with Mavenclad (cladribine tablets) for patients with highly active relapsing forms of multiple sclerosis (MS). The post-hoc analysis, āEfficacy of Cladribine Tablets in high disease activity subgroups of patients…
May 3, 2018 News by Janet Stewart, MSc Past, Present and Possible Future Directions of MS Research Topic of Educational Talk TheĀ science underlying our understanding of multiple sclerosis ā through to new technologies that might expand that understanding in ways “never imagined” ā was the focus of a recentĀ educational webinar titled āThe Evolving Science of Multiple Sclerosis (MS).ā Kottil Rammohan, MD,Ā a professor of clinical neurology and director of the…
April 11, 2018 News by Alice MelĆ£o, MSc Mavenclad Approved by United Arab Emirates to Treat Highly Active Relapsing MS The United Arab Emirates is the first country in the Middle East and Africa to approve Mavenclad (cladribine tablets) as a treatment for patients with highly active relapsing multiple sclerosis (MS) evidenced through imaging tests or clinical evaluation. The therapy is expected to become available once local regulatory…
March 15, 2018 News by Patricia Inacio, PhD New Spherix Report Finds PPMS Treatment Increased Significantly in Past Year Since Genentech‘sĀ OcrevusĀ was approvedĀ a year ago, the treatment rate of primary progressive multiple sclerosis (PPMS)Ā has increased significantly. However, a closer look at the data shows that other disease-modifying therapies (DMTs) are equally responsible for this increase. The findings were reported byĀ Spherix Global InsightsĀ in their new study…
February 27, 2018 Columns by Ed Tobias What’s Hot and What’s Not Among MS Therapies? The newest kids on the MS block, disease-modifying therapies (DMT) such as Genentech’s Ocrevus (ocrelizumab) and Sanofi Genzyme’s Lemtrada (alemtuzumab), are attracting a lot of interest these days. But, some DMTs that have been around for more than two decades are still being prescribed by a lot of neurologists.
February 27, 2018 News by Iqra Mumal, MSc Comorbidities Among MS Patients in US Range from High Cholesterol and Blood Pressure to Anxiety, Study Reports Comobidities are common in multiple sclerosis (MS) patients in the U.S., with the mostĀ frequent being high cholesterolĀ and blood pressure, followed by gastrointestinal disease, thyroid disease, and anxiety, a database analysis reports. But distinctions exist between the sexes, this claims analysis found. High cholesterol and blood pressure, as well as diabetes…
November 21, 2017 News by Larry Luxner Patients Tell Their Stories in Consortium of Multiple Sclerosis Centers’ Online Videos Maryland special education teacher Ingrid Hanson says that since she was diagnosed with multiple sclerosis five years ago, sheās developed a better understanding of her students’ needs and the importance of teamwork. Flavia Nelson helps treat MS in the Hispanic community in Houston. Flavia Nelson, an MS specialist at…
June 8, 2017 News by Charles Moore ‘MS from the Inside Out’ Uses Virtual Reality to Share What Life for Patients Is Like Virtual reality (VR) technology is most commonlyĀ associated with gaming and entertainment, but it’s expanding intoĀ a variety of clinical and healthcare applications.Ā The Ontario-based biopharmaceutical firm EMD Serono, Canada, is now using VR as an informational and educational tool to provide a more profound understanding of what living with multiple sclerosis…
June 1, 2017 News by Patricia Silva, PhD EMD Serono Launches MS Care Partner Survey with IACO to Honor May 31, World MS Day 2017 ToĀ honor World MS Day, May 31,Ā EMD SeronoĀ launched a multiple sclerosis care partner survey in collaboration with the International Alliance of Carer Organizations (IACO). The new survey comes after the initial results from aĀ MerckĀ studyĀ showed that the highest number of MS care partners are aged 18-34, and that…
May 30, 2017 News by Joana Fernandes, PhD #CMSC17 – Cladribine Reduced Annual MS Relapse Rate by 55% to 57%, Trials Show Cladribine tablets reduced relapsing multiple sclerosis patients’ annual relapse rate by 55 to 57 percent, depending on the dose, according to clinical trials. EMD Serono, a unit of Cladribine’s developer, Merck,Ā presented the trial results at the 31st annual meeting of the Consortium of Multiple Sclerosis CentersĀ in New Orleans,…
March 31, 2017 News by Charles Moore ‘My Story’ Opens, Giving a Shared Voice to People Dealing with Challenges of MS AsĀ the challenge of living with multiple sclerosis (MS) often leaves patients feeling isolated and depressed, the biopharmaceutical firm EMD Serono has launched an online storytelling platform calledĀ My Story. The platform is designed to be an empowering and therapeutic support resource for patients and caregivers in their struggles with MS.
June 3, 2016 News by InĆŖs Martins, PhD #CMSC16 – Medical Affairs VP at EMD Serono Discusses MS Drug Rebif, MS LifeLines Support in Exclusive Interview EMD Serono,Ā the U.S. and Canadian subsidiary and biopharmaceutical business of Merck KGaA,Ā focuses exclusively on specialty care. With expertise inĀ fertility, endocrinology, oncology and neurology, the company is featuring several innovative products with therapeutic potential in the oncology, immuno-oncology, and immunology fields. Rebif (interferon beta-1a), EMD Serono’s therapyĀ for patients withĀ relapsing…
May 23, 2016 News by Patricia Silva, PhD #CMSC16 – EMD Serono’s Dr. Rick Munschauer Discusses Value of Annual Meeting With theĀ Consortium of Multiple Sclerosis Centers (CMSC) 2016 fast approaching, Multiple Sclerosis News TodayĀ sat down with a man of far-reaching interest in multiple sclerosis (MS) Ā ā Dr. Rick Munschauer, Vice President of Medical Affairs, Neurology and Immunology at…
January 22, 2016 News by Patricia Silva, PhD EMD Serono Gains Exclusive US Rights to MS Drug for Relapsing Forms of Disease EMD Serono, theĀ North American biopharmaceutical business arm of Merck, announced it has gained exclusive rights over RebifĀ (interferon beta-1a) inĀ the United States. RebifĀ Ā is a treatment for relapsing forms of multiple sclerosis (MS). Rebif, an approved drug, is usedĀ to decrease the frequency of MS relapses and delay the occurrence of…
October 15, 2015 News by Patricia Silva, PhD EMD Serono Announces Publication of PRISMS-15 Years Follow-up Study Results on Rebif for RelapsingāRemitting Multiple Sclerosis EMD Serono, the U.S. biopharmaceutical division of Merck KGaA, Darmstadt, Germany, recently announced that the results of the 15 year follow-up trial PRISMS-15 (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) evaluating RebifĀ® (interferon beta-1a), a high-dose, high-frequency interferon beta for the treatment of…
September 28, 2015 News by Patricia Silva, PhD EMD Serono To Present New Data on Rebif, a Therapy for RRMS, at Upcoming ECTRIMS Congress EMD Serono, the subsidiary of Merck KGaA in the United States, recently announced that it will present new data on RebifĀ®, an interferon beta-1a therapy for relapsing-remitting multiple sclerosis (RRMS), at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be…
October 7, 2014 News by Patricia Silva, PhD Oklahoma Medical Research Foundation Receives Multiple Sclerosis Innovation Grant A scientist from the Oklahoma Medical Research Foundation (OMRF) is the recipient of 1 of only 5 Multiple Sclerosis Innovation grants from German biopharmaceutical company EMD Serono. Manu Nair, the foundation’s Vice President of Technology Ventures, said that this funding from a new collaborative relationship is a crucial step towards…
September 19, 2014 News by Patricia Silva, PhD Accelerated Cure Project for MS, EMD Serono To Study Treatment Outcomes The nonprofit organization Accelerated Cure Project for Multiple Sclerosis is going to sponsor the launch of theĀ Optimizing Treatment – Understanding Progression (OPT-UP) study in collaboration with biopharmaceutical companyĀ EMD Serono, Inc, a subsidiary of the german Merck KGaA. The study will enroll 2,500 MS…
September 12, 2014 News by Patricia Silva, PhD EMD Serono’s Multiple Sclerosis Pipeline On Display at 2014 ACTRIMS-ECTRIMS Meeting in Boston During the joint meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS), taking place in Boston from September 10-13, EMD Serono, Inc., a subsidiary of Merck KGaA, will present new data from its multiple sclerosis…